European Journal of Epidemiology

, Volume 18, Issue 7, pp 665–670

Delivery outcome after the use of meclozine in early pregnancy

  • Bengt Källén
  • Isabelle Mottet


In some countries, including Sweden, no risk is considered to exist with the use of meclozine for nausea and vomiting in pregnancy (NVP), but in other countries warnings against use during pregnancy are given. Rat tests indicate a teratogenic risk and published epidemiological studies are of restricted size. Delivery outcome was studied in 16,536 women who reported the use of meclozine in early pregnancy and was compared with all 540,660 women who gave birth. Information on drug usage was obtained prospectively in early pregnancy. Risk factors for using meclozine were young maternal age, to have had a previous child, not to smoke, to have a low body mass index. The use of some other drugs (antihypertensives, thyroxine, anticonvulsants) decreased the use of meclozine. Maternal diagnoses of preeclampsia or diabetes were less frequent when the woman had used meclozine. The twinning rate was increased and the sex distribution of the infants low (female excess). Preterm birth, low birth weight, short body length, and small head circumference occurred at a reduced rate after meclozine use, notably for boys. Also the rate of congenital malformations was reduced. If anything, delivery outcome is better than expected when the mother used meclozine. These beneficial effects are probably secondary to NVP. Meclozine can apparently be used without risk at this condition.

Congenital malformations Meclozine Nausea and vomiting in pregnancy Preterm birth 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    King CT. Teratogenic effect of meclizine hydrochloride on the rat. Science 1983; 141: 353–355.Google Scholar
  2. 2.
    Giurges M, Pudgdevall J. Experimental teratology with meclozine. Med Exp 1966; 15: 375–388.Google Scholar
  3. 3.
    Nelson MM, Forfar JO. Association between drug administration during pregnancy and congenital abnormalities of the fetus. Br Med J 1971; i: 523–527.Google Scholar
  4. 4.
    Greenberg G, Inman WhW, Weatherall JAC, Adelskin AM, Haskey JC. Maternal drug history and congenital abnormalities. Br Med J 1977; ii: 853–856.Google Scholar
  5. 5.
    Shapiro S, Kaufman DW, Rosenberg L, et al. Meclizine in pregnancy in relation to congenital malformations. Br Med J 1978; i: 483.Google Scholar
  6. 6.
    Milkovich L, van der Berg BJ. An evaluation of the teratogenicity of certain antinauseant drug. Am J Obst Gynecol 1983; 125: 244–248.Google Scholar
  7. 7.
    Cnattingius S, Ericson A, Gunnarskog J, Källén B. A quality study of a medical birth registry. Scand J Soc Med 1990; 18: 143–148.Google Scholar
  8. 8.
    Källén B. Search for teratogenic risks with the aid of malformation registries. Teratology 1987; 35: 47–52.Google Scholar
  9. 9.
    Källén B. A birth weight for gestational age standard based on data in the Swedish Medical Birh Registry, 1985-1989. Eur J Epidemiol 1995; 11: 601–606.Google Scholar
  10. 10.
    Yerushalmy J, Milkovich L. Evaluation of the teratogenic effect of meclizine in man. Am J Obst Gynecol 1965; 93: 553–562.Google Scholar
  11. 11.
    Kullander S, Källén B. A prospective study of drugs and pregnancy. II. Antiemetic drugs. Acta Obst Gynecol Scand 1976; 55:105–111.Google Scholar
  12. 12.
    Lacroix R, Eason E, Melzack R. Nausea and vomiting during pregnancy: A prospective study of its frequency, intensity, and patterns of change. Am J Obst Gynecol 2000; 182: 931–937.Google Scholar
  13. 13.
    Clausson B, Granath F, Ekbom A, et al. Effect of caffeine exposure during pregnancy on birth weight and gestational age. Am J Epidemiol 2002; 158: 429–436.Google Scholar
  14. 14.
    Seto A, Einarson T, Koren G. Pregnancy outcome following first trimester exposure to antihistamines: Meta-analysis. Am J Perinatol 1994; 14: 119–124.Google Scholar
  15. 15.
    Magee LA, Mazzotta P, Koren G. Evidence-based view of safety and effectiveness of pharmacologic therapy for nausea and vomiting of pregnancy (NVP). Am J Obst Gynecol 2002; 186(Suppl 2): 256–261.Google Scholar
  16. 16.
    Källén B. Use of antihistamine drugs in early pregnancy and delivery outcome. J Maternal-Fetal Neonatal Med 2002; 11: 146–152.Google Scholar

Copyright information

© Kluwer Academic Publishers 2003

Authors and Affiliations

  • Bengt Källén
    • 1
  • Isabelle Mottet
    • 2
  1. 1.Tornblad InstituteUniversity of LundLundSweden
  2. 2.UCB PharmaGlobal Drug SafetyBelgium

Personalised recommendations